GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (NAS:ACHV) » Definitions » Other Income (Expense)

Achieve Life Sciences (Achieve Life Sciences) Other Income (Expense) : $-0.54 Mil (TTM As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Achieve Life Sciences Other Income (Expense)?

Achieve Life Sciences's other income expense for the Achieve Life Sciences's pretax income for the three months ended in Dec. 2023 was $-0.51 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.54 Mil.


Achieve Life Sciences Other Income (Expense) Historical Data

The historical data trend for Achieve Life Sciences's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achieve Life Sciences Other Income (Expense) Chart

Achieve Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 -0.05 -0.08 0.04 -0.54

Achieve Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 - -0.01 -0.02 -0.51

Achieve Life Sciences Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Achieve Life Sciences  (NAS:ACHV) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.


Achieve Life Sciences (Achieve Life Sciences) Business Description

Traded in Other Exchanges
Address
22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.
Executives
John Bencich officer: CFO and PFO 2401 FOURTH AVENUE, SUITE 1050, SEATTLE WA 98121
Stuart Duty director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Sellig director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Braxton King director 91 JAMES AVENUE, ATHERTON CA 94027
Dialectic Life Sciences Spv Llc 10 percent owner C/O DIALECTIC LS MANAGER LLC, 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Ls Manager Llc 10 percent owner 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
John Fichthorn 10 percent owner C/O DIALECTIC CAPITAL MANAGEMENT, LLC, 17 STATE STREET, SUITE 3930, NEW YORK NY 10004
Dialectic Capital Management, Lp 10 percent owner 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Partners, Llc 10 percent owner 2ND FLOOR 119 ROWAYTON AVE, NORWALK CT 06853
Vaughn B Himes director C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Financial Group Svb 10 percent owner 2270 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii, Llc 10 percent owner 2770 SAND HILL ROAD, MENLO CITY CA 94025
Svb Innovation Credit Fund Viii, L.p. 10 percent owner C/O SVB INNOVATION CREDIT PARTNERS VIII, 2770 SAND HILL ROAD, MENLO PARK CA 94025
Innovation Credit Fund Viii-a, L.p. 10 percent owner 2770 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii-a, Llc 10 percent owner 2770 SAND HILL ROAD, MENLO CITY CA 94025